Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Perceptions of the Veterinary Profession among Human Health Care Students before an Inter-Professional Education Course at Midwestern University.

Englar RE, Show-Ridgway A, Noah DL, Appelt E, Kosinski R.

J Vet Med Educ. Fall 2018;45(3):423-436. doi: 10.3138/jvme.1016-161r1. Epub 2017 Nov 3.

PMID:
29099320
2.

Survey of intestinal parasitism in dogs in the Phoenix metropolitan area.

Cornell HN, O'Neal PR, Wong VM, Noah DL.

J Am Vet Med Assoc. 2017 Sep 1;251(5):539-543. doi: 10.2460/javma.251.5.539.

PMID:
28828960
3.

One Health: Children, Waterfowl, and Lead Exposure in Northwestern Nigeria.

Edwards JR, Fossum TW, Nichols KJ, Noah DL, Tarpley RJ, Prozialeck WC.

J Am Osteopath Assoc. 2017 Jun 1;117(6):370-376. doi: 10.7556/jaoa.2017.075. Review.

PMID:
28556859
4.

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Rasid O, Vlase E, Coman C, Caras I, Ghiorghisor A, Berbecila L, Tofan V, Bowen RA, Marlenee N, Hartwig A, Bielefeldt-Ohmann H, Baldwin SL, Van Hoeven N, Vedvick TS, Huynh C, O'Hara MK, Noah DL, Fox CB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.

5.

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Clin Vaccine Immunol. 2015 Nov 11;23(1):73-7. doi: 10.1128/CVI.00475-15. Print 2016 Jan.

6.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR.

JAMA. 2015 Jul 21;314(3):237-46. doi: 10.1001/jama.2015.7916.

PMID:
26197184
7.

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Mulligan MJ, Bernstein DI, Frey S, Winokur P, Rouphael N, Dickey M, Edupuganti S, Spearman P, Anderson E, Graham I, Noah DL, Mangal B, Kim S, Hill H, Whitaker J, Emery W, Beck A, Stephens K, Hartwell B, Ogilvie M, Rimann N, Osinski E, Destefano E, Gajadhar T, Strudwick A, Pierce K, Lai L, Yue L, Wang D, Ying C, Cline A, Foltz T, Wagner N, Dull G, Pacatte T, Taggart B, Johnson V, Haller L, Looney C, Li S, May M, Myers B, May R, Parker L, Cochran N, Bowen D, Bell M, Scoggins J, Burns A, Stablein C, Wolff M, Jolles B, Leung B, Lambert L, Shorer S, Buchanan W, Murray S, Chang S, Gorman R.

Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.

8.

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Open Forum Infect Dis. 2014 Oct 8;1(3):ofu091. doi: 10.1093/ofid/ofu091. eCollection 2014 Dec.

9.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.

10.

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group.

JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854.

PMID:
25291577
11.

Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Kotloff KL, Halasa NB, Harrison CJ, Englund JA, Walter EB, King JC, Creech CB, Healy SA, Dolor RJ, Stephens I, Edwards KM, Noah DL, Hill H, Wolff M.

Pediatr Infect Dis J. 2014 Aug;33(8):865-71. doi: 10.1097/INF.0000000000000329.

12.

Adapting global influenza management strategies to address emerging viruses.

Noah DL, Noah JW.

Am J Physiol Lung Cell Mol Physiol. 2013 Jul 15;305(2):L108-17. doi: 10.1152/ajplung.00105.2013. Epub 2013 May 24. Review.

13.

Host gene expression signatures discriminate between ferrets infected with genetically similar H1N1 strains.

Ljungberg K, McBrayer A, Camp JV, Chu YK, Tapp R, Noah DL, Grimes S, Proctor ML, Liljeström P, Jonsson CB, Bruder CE.

PLoS One. 2012;7(7):e40743. doi: 10.1371/journal.pone.0040743. Epub 2012 Jul 13.

14.

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, Turley CB, Rupp RE, Hill H, Wolff M, Noah DL, Ross AC, Cress G, Belshe RB.

J Infect Dis. 2012 Sep 15;206(6):828-37. doi: 10.1093/infdis/jis445. Epub 2012 Jul 16.

15.

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.

Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC.

J Infect Dis. 2012 Sep 15;206(6):811-20. doi: 10.1093/infdis/jis427. Epub 2012 Jul 10.

16.

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group.

Vaccine. 2012 Jun 13;30(28):4240-8. doi: 10.1016/j.vaccine.2012.04.044. Epub 2012 Apr 23.

17.

Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).

Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, Noah DL.

Life Sci. 2012 Mar 10;90(11-12):440-5. doi: 10.1016/j.lfs.2011.12.014. Epub 2012 Jan 16.

18.

Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.

Jackson LA, Patel SM, Swamy GK, Frey SE, Creech CB, Munoz FM, Artal R, Keitel WA, Noah DL, Petrie CR, Wolff M, Edwards KM.

J Infect Dis. 2011 Sep 15;204(6):854-63. doi: 10.1093/infdis/jir440.

19.
20.

A roundtable discussion on emerging infectious diseases--risks to U.S. service members in Afghanistan and Iraq.

Gaydos JC, Tomich N, Russell KL, Jordan NN, Aronson N, Roselle GA, Khabbaz RF, Batsel-Stewart T, Gould PL, Erdtmann R, DeFraites RF, Noah DL.

Mil Med. 2010 Dec;175(12):937-8. No abstract available.

PMID:
21265296
21.

Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret.

McBrayer A, Camp JV, Tapp R, Yamshchikov V, Grimes S, Noah DL, Jonsson CB, Bruder CE.

Virol J. 2010 Jul 9;7:149. doi: 10.1186/1743-422X-7-149.

22.

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H.

Vaccine. 2009 Nov 5;27(47):6642-8. doi: 10.1016/j.vaccine.2009.03.015. Epub 2009 Mar 25.

23.

Influenza virus M2 protein inhibits epithelial sodium channels by increasing reactive oxygen species.

Lazrak A, Iles KE, Liu G, Noah DL, Noah JW, Matalon S.

FASEB J. 2009 Nov;23(11):3829-42. doi: 10.1096/fj.09-135590. Epub 2009 Jul 13.

24.

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.

Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H.

Vaccine. 2009 Aug 13;27(37):5091-5. doi: 10.1016/j.vaccine.2009.06.057. Epub 2009 Jul 3.

25.

Influenza exerts continued pressure in an era of modern medicine.

Noah JW, Noah DL, Matalon S.

Am J Respir Cell Mol Biol. 2009 Jul;41(1):3-7. doi: 10.1165/rcmb.2009-0158ED. Epub 2009 May 7. No abstract available.

26.

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

Noah DL, Hill H, Hines D, White EL, Wolff MC.

Clin Vaccine Immunol. 2009 Apr;16(4):558-66. doi: 10.1128/CVI.00368-08. Epub 2009 Feb 18.

27.

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, He F, Noah DL, Hill H.

J Infect Dis. 2008 Nov 1;198(9):1309-16. doi: 10.1086/592172.

28.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.

J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916.

PMID:
18694338
29.

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H.

J Infect Dis. 2008 Mar 1;197(5):667-75. doi: 10.1086/527489.

PMID:
18260764
30.

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.

Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J.

J Infect Dis. 2008 Feb 15;197(4):580-3. doi: 10.1086/526537.

PMID:
18237269
31.

Department of Defense Global Emerging Infections Surveillance and Response System Indian Ocean tsunami response.

Chretien JP, Glass JS, Coldren RC, Noah DL, Hyer RN, Gaydos JC, Malone JL.

Mil Med. 2006 Oct;171(10 Suppl 1):12-4.

PMID:
17447614
32.

A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals.

Noah JW, Severson W, Noah DL, Rasmussen L, White EL, Jonsson CB.

Antiviral Res. 2007 Jan;73(1):50-9. Epub 2006 Jul 28.

PMID:
16904762
33.

Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines.

Sirén J, Imaizumi T, Sarkar D, Pietilä T, Noah DL, Lin R, Hiscott J, Krug RM, Fisher PB, Julkunen I, Matikainen S.

Microbes Infect. 2006 Jul;8(8):2013-20. Epub 2006 May 22.

PMID:
16797201
34.

The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target.

Twu KY, Noah DL, Rao P, Kuo RL, Krug RM.

J Virol. 2006 Apr;80(8):3957-65.

35.

Influenza virus virulence and its molecular determinants.

Noah DL, Krug RM.

Adv Virus Res. 2005;65:121-45. No abstract available.

PMID:
16387195
36.

Military medical education: nuclear, biological, and chemical medical defense training as a model for planners.

Cieslak TJ, Pavlin JA, Noah DL, Dire DJ, Stanek SA, Kortepeter MG, Jarrett DG, Pastel RH, Darling RG, Jacocks JM, Hurst CG, Richards BA, Eitzen EM Jr.

Mil Med. 2004 May;169(5):337-41. No abstract available.

PMID:
15185995
37.
38.

Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein.

Krug RM, Yuan W, Noah DL, Latham AG.

Virology. 2003 May 10;309(2):181-9. Review. No abstract available.

40.

Biological terrorism against animals and humans: a brief review and primer for action.

Noah DL, Noah DL, Crowder HR.

J Am Vet Med Assoc. 2002 Jul 1;221(1):40-3. Review. No abstract available.

PMID:
12420822
41.

The history and threat of biological warfare and terrorism.

Noah DL, Huebner KD, Darling RG, Waeckerle JF.

Emerg Med Clin North Am. 2002 May;20(2):255-71.

PMID:
12120479
42.

Interferon regulatory factor-1, interferon-beta, and reovirus-induced myocarditis.

Azzam-Smoak K, Noah DL, Stewart MJ, Blum MA, Sherry B.

Virology. 2002 Jun 20;298(1):20-9.

43.
44.

Agroterrorism, biological crimes, and biowarfare targeting animal agriculture. The clinical, pathologic, diagnostic, and epidemiologic features of some important animal diseases.

Wilson TM, Gregg DA, King DJ, Noah DL, Perkins LE, Swayne DE, Inskeep W 2nd.

Clin Lab Med. 2001 Sep;21(3):549-91. Review.

PMID:
11572141
45.

Ten great veterinary public health/preventive medicine achievements in the United States, 1901 to 2000.

Noah DL, Grayson JK, Caudle LC 3rd.

J Am Vet Med Assoc. 2000 Dec 15;217(12):1834-6. No abstract available.

PMID:
11132887
46.

Biological terrorism and veterinary medicine in the United States.

Ashford DA, Gomez TM, Noah DL, Scott DP, Franz DR.

J Am Vet Med Assoc. 2000 Sep 1;217(5):664-7. Review. No abstract available.

PMID:
10976296
47.

Biological warfare training. Infectious disease outbreak differentiation criteria.

Noah DL, Sobel AL, Ostroff SM, Kildew JA.

Ann N Y Acad Sci. 1999;894:37-43. Review.

PMID:
10681967
48.
49.

Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure.

Roels TH, Bloom AS, Buffington J, Muhungu GL, Mac Kenzie WR, Khan AS, Ndambi R, Noah DL, Rolka HR, Peters CJ, Ksiazek TG.

J Infect Dis. 1999 Feb;179 Suppl 1:S92-7.

PMID:
9988170
50.

Chronic multisymptom illness affecting Air Force veterans of the Gulf War.

Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC.

JAMA. 1998 Sep 16;280(11):981-8.

PMID:
9749480

Supplemental Content

Support Center